Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib versus crizotinib in untreated ALK-positive advanced non-small cell lung cancer
NL-OMON50594Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Brigatinib with Crizotinib (2 arms). Primary endpoint: Progression-free survival. Started Oct 2016; status: active, not recruiting.
02
Drugs
brigatinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON50594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50594.